PMGC Holdings Inc.
ELABHealthcare|Biotechnology|US
$1.61
-0.04 (-2.42%)
DCF Value
$847.13
Tangible Book / Share
$15.81
Cash / Share
$38.54
About
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
Stock Price
-100.0%(1Y)
1M
-48.6%
3M
-82.4%
6M
-91.9%
YTD
-99.9%
1Y
-100.0%
3Y
-100.0%
5Y
-100.0%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$1.3M
Employees32 (+1500% YoY)
CEOGraydon Bensler
IPO DateNov 21, 2023
Beta-0.27
52-Week Range$1.56 – $1471.2
Avg Volume270,562
ExchangeNASDAQ
Websitepmgcholdings.com
Ownership
Float94.4%
Shares Outstanding0.8M
Recent Insider Trades
Parry JeffreyAWARD
Jun 1, 202675,046 shares @ $1.77
Kovalyov GeorgeAWARD
Jun 1, 202675,046 shares @ $1.77
Daley JulianaAWARD
Jun 1, 202675,046 shares @ $1.77
Braeden LichtiAWARD
Jun 1, 2026450,277 shares @ $1.77
Parry JeffreyOTHER
Nov 13, 20230 shares
Peers
Recent News
NorthStrive Biosciences Announces Results from EL-32 Preclinical Combination Study with Semaglutide and Plans for Next Phase of Development
Nov 5, 2026 · globenewswire.com
PMGC Holdings Inc. Announces DBA as NorthStrive Holdings, Inc., Trademark License Agreement, and Website Update
Oct 8, 2026 · globenewswire.com
PMGC Holdings (Nasdaq: ELAB) Announces Completion of $100 Million SPAC IPO, Launching NorthStrive Acquisition Corp. I (Nasdaq: NSAI) as First in Planned SPAC Sponsorship Franchise to Expand M&A Strategy
Oct 1, 2026 · globenewswire.com
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs
Sep 29, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:08 AM